Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors

Pediatric Transplantation

Volumn 13, Issue 6, 2009, Pages 746-753

  Suminoe, Aiko ^a   Matsuzaki, Akinobu ^a   Hattori, Hiroyoshi ^a   Koga, Yuhki ^a   Hara, Toshiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Autologous peripheral blood stem cell transplantation; Cancer immunotherapy; Childhood cancer; Dendritic cell; Tumor antigen; Tumor lysate; Tumor specific peptides

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DENDRITIC CELL VACCINE; ETOPOSIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IFOSFAMIDE; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; PIRARUBICIN; THIOTEPA; TUMOR ANTIGEN; VINCRISTINE;

ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; EWING SARCOMA; FEMALE; FUSION GENE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; MALIGNANT NEOPLASTIC DISEASE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; NATURAL KILLER T CELL; NEUROBLASTOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; REMISSION; SCHOOL CHILD; SKIN MANIFESTATION; SOLID TUMOR; SYNOVIAL SARCOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-4; KILLER CELLS, NATURAL; MALE; NEOPLASMS; NEUROBLASTOMA; PEPTIDES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SARCOMA; SARCOMA, EWING'S;

EID: 68849107068     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.01066.x     Document Type: Article

References (33)

1. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 2005 : 17 : 163 169.
2. Sheng KC, Pietersz GA, Wright MD, Apostolopoulos V. Dendritic cells: Activation and maturation - applications for cancer immunotherapy. Curr Med Chem 2005 : 12 : 1783 1800.
3. Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: Mapping the way. Nat Med 2004 : 10 : 475 480.
4. Den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ. Dendritic cells: Tools and targets for antitumor vaccination. Expert Rev Vaccines 2005 : 4 : 699 710.
5. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005 : 5 : 296 306. (Pubitemid 40516155)
6. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004 : 10 : 909 915.
7. Hersey P, Menzies SW, Halliday GM, et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2004 : 53 : 125 134.
8. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002 : 195 : 1279 1288.
9. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001 : 61 : 6451 6458.
10. Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003 : 21 : 135 142.
11. Holtl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002 : 8 : 3369 3376.
12. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001 : 98 : 8809 8814.
13. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001 : 61 : 8513 8519.
14. Matsuzaki A, Suminoe A, Hattori H, Hoshina T, Hara T. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol 2002 : 24 : 220 223.
15. Geiger J, Hutchinson R, Hohenkirk L, Mckenna E, Chang A, Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000 : 356 : 1163 1165.
16. Rousseau RF, Brenner MK. Vaccine therapies for pediatric malignancies. Cancer J 2005 : 11 : 331 339.
17. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994 : 331 : 294 299.
18. Sreekantaiah C, Ladanyi M, Rodriguez E, Chaganti RS. Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms. Am J Pathol 1994 : 144 : 1121 1134.
19. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999 : 50 : 213 219.
20. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998 : 4 : 328 332.
21. Picker LJ, Singh MK, Zdraveski Z, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995 : 86 : 1408 1419.
22. Cox JH, Desouza M. Evaluation of natural killer cell activity. Mol Biotechnol 2000 : 15 : 147 154.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 : 92 : 205 216.
24. Borg C, Jalil A, Laderach D, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004 : 104 : 3267 3275.
25. Vitale M, Della Chiesa M, Carlomagno S, et al. The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 2004 : 34 : 1715 1722.
26. Mocikat R, Braumuller H, Gumy A, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003 : 19 : 561 569.
27. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004 : 5 : 996 1002.
28. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: A mechanism of action for clinical activity. Cancer Immunol Immunother 2006 : 55 : 1122 1131.
29. Woo CY, Clay TM, Lyerly HK, Morse MA, Osada T. Role of natural killer cell function in dendritic cell-based vaccines. Expert Rev Vaccines 2006 : 5 : 55 65.
30. Kundu SK, Engleman E, Benike C, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998 : 14 : 551 560.
31. Asavaroengchai W, Kotera Y, Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 2002 : 99 : 931 936.
32. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004 : 53 : 275 306.
33. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005 : 5 : 263 274.